Vir Biotechnology Inc
$ 8.52
3.27%
11 Jun - close price
- Market Cap 1,436,915,000 USD
- Current Price $ 8.52
- High / Low $ 8.63 / 8.26
- Stock P/E N/A
- Book Value 5.49
- EPS -3.13
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -0.48 %
- 52 Week High 11.66
- 52 Week Low 4.16
About
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California.
Analyst Target Price
$21.56
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-23 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -0.85 | -0.31 | -1.17 | -0.8 | -0.88 | -0.76 | -1.56 | -1.02 | -0.48 | -0.86 | -1.22 | -1.45 |
| Estimated EPS | 0.48 | -0.54 | -0.84 | -0.72 | -0.88 | -0.89 | -1.08 | -0.89 | -1.05 | -1.01 | -1.19 | -1.19 |
| Surprise | -1.33 | 0.23 | -0.33 | -0.08 | 0 | 0.13 | -0.48 | -0.13 | 0.57 | 0.15 | -0.03 | -0.26 |
| Surprise Percentage | -277.0833% | 42.5926% | -39.2857% | -11.1111% | 0% | 14.6067% | -44.4444% | -14.6067% | 54.2857% | 14.8515% | -2.521% | -21.8487% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.84 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VIR
2026-06-11 22:40:06
Vir Biotechnology director Timothy Coughlin filed an initial Form 3, reporting zero beneficial ownership of the company's common stock as of June 9, 2026. This SEC filing establishes his initial position as an insider, showing no direct holdings. A Form 3 is required when an individual becomes an officer, director, or large shareholder to disclose their initial securities ownership.
2026-06-11 13:09:00
Morgan Stanley has increased its price target for Vir Biotechnology (NASDAQ:VIR) to $27.00 from $23.00, maintaining an "overweight" rating. This adjustment suggests a potential upside of 227.27% from the current stock price. Despite weak recent earnings, insider selling, and mixed analyst opinions, the stock holds a "Moderate Buy" consensus rating with an average target of $20.88.
2026-06-11 11:09:55
Vir Biotechnology (NASDAQ:VIR) has announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026. Coughlin brings extensive financial and biotechnology experience, having previously served as CFO of Neurocrine Biosciences and holding various board positions. This appointment comes as Vir navigates a growth phase with a strong cash position but ongoing cash burn from clinical programs, and follows recent financial shortfalls and upcoming presentation of Phase 2 trial data.
2026-06-11 06:40:06
Vir Biotechnology, Inc. announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. Coughlin, former CFO of Neurocrine Biosciences, brings extensive experience in finance and strategic development from his roles in a fully integrated commercial pharmaceutical company and various other boards. His expertise is expected to be highly valuable as Vir Biotechnology advances its portfolio in infectious diseases and cancer.
2026-06-10 20:39:21
Vir Biotechnology, Inc. has announced the appointment of Timothy Coughlin, CPA, to its Board of Directors, increasing the board size from seven to eight members. Coughlin will serve as a Class III director until the 2028 annual meeting and has also been appointed Chair of the Audit Committee. He will receive standard non-employee director compensation, including stock options and restricted stock units, and there are no disclosed related party transactions.
2026-06-10 18:48:31
Vir Biotechnology, Inc. (Nasdaq: VIR) has announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. Coughlin, former CFO of Neurocrine Biosciences, brings extensive experience in finance and biotechnology leadership. He is expected to contribute to the company's advancement of treatments for hepatitis delta and its pipeline of T-cell engagers.
